ClinicalTrials.gg
CompletedNCT03009019Updated Jan 10, 2023Results posted

Efficacy, Tolerability, and Safety of DFN-15

A Phase 3 interventional study of DFN-15 Active and DFN-15 Placebo in Migraine Headache, sponsored by BioDelivery Sciences International. Completed at 43 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-01-10.

Sponsored by BioDelivery Sciences International · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
631
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 696 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
83rd of 609
631 · median 78
Started
2016
with 42 others
Phase 3
136 of 696
20 open now
Registered
329th of 696
by date

Among the 696 studies in Migraine Disorders with a site in United States, this one is the 83rd largest by enrollment of the 609 interventional ones that give a count, is one of 43 that started in 2016, is one of 136 in phase 3, and was the 329th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

93 of the 696 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 696 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States

03

Conditions studied

  • Migraine Headache

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A history of episodic migraine, who experience 2 to 8 migraine attacks per month for at least the past 12 months, with no more than 14 headache days per month, and with 48 hours of headache-free time between migraine attacks.
  2. Patients who have migraine with or without aura with onset before age 50 years
  3. Report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain severity scale without treatment.
  4. Subjects who are willing and able to:

    1. Evaluate and record pain, migraine symptoms, and study drug effectiveness information in real-time using a subject eDiary for the duration of the study;
    2. Record each instance of the use of study drug and rescue medication in real-time using a subject eDiary for the duration of the study;
    3. Comply with all other study procedures and scheduling requirements.

Exclusion criteria

Exclusion Criteria:

  1. Minors, even if they are in the specified study age range
  2. Medication overuse:

    1. Opioids greater than or equal to 10 days during the 90 days prior to screening
    2. Combination medications (e.g., Fiorinal®) greater than or equal to 10 days during the 90 days prior to screening (applies only if includes opioid and/or barbiturate)
    3. Nonsteroidal Anti-inflammatory Drugs or other simple medications greater than 14 days a month during the 90 days prior to screening
    4. Triptans or ergots greater than or equal to 10 days a month during the 90 days prior to screening
  3. Treated with onabotulinumtoxin A (Botox®) for migraine within 4 months prior to screening. (If treated for cosmetic reasons, subjects may be included).
  4. Current treatment with antipsychotics or use of antipsychotics within 30 days prior to randomization.
  5. Patients who have received treatment with an drug or device within 30 days of randomization, or participated in a central nervous system clinical trial within 2 months prior to randomization
  6. Patients with positive screening test for [HIV], positive surface antigen (HBsAg), or positive virus [HCV] antibody
  7. Subjects who are employees or immediate relatives of the employees of the Sponsor, any of its affiliates or partners, or of the clinical research study site.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
631 participants (actual)

Study arms

  • Experimental
    DFN-15 Active

    DFN-15 Active

    Drug: DFN-15 Active

  • Placebo comparator
    DFN-15 Placebo

    DFN-15 Placebo

    Other: DFN-15 Placebo

Interventions

  • DrugDFN-15 Active

    Also known as: Celecoxib Oral Solution

  • OtherDFN-15 Placebo
06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (First Treated Double-blind Treatment Period)

    The primary efficacy end point (for first treated DB1 attack only) were the percentage of subjects who were pain-free 2 hours postdose compared between DFN-15 and placebo (defined as a reduction from predose moderate \[Grade 2\] or severe \[Grade 3\] pain to none \[Grade 0\]

    Time frame: 2 hours postdose

  2. Percentage of Subjects Who Are Free From Their MBS at 2 Hours Postdose

    Percentage of subjects who are free from their Most Bothersome Symptom (MBS) among nausea, photophobia, and phonophobia (first double-blind treatment period)

    Time frame: 2 hours postdose

Secondary outcomes

  1. The Number of Subjects With TEAEs After Study Drug Compared Between DFN-15 and Placebo

    For DB1: TEAE that started or worsening of a pre-existing condition on or after the first dose of study drug (DFN-15 or placebo) in to taking DB2 study drug, whichever occurs first. For DB2: TEAE that started or worsened on or after the first dose of study drug in DB2 up to 5 days after the date of the last dose of study drug in DB2.

    Time frame: Per protocol, the maximum dosing timeframe for DB2 was 10 weeks; therefore, the maximum AE collection window was 11 weeks total.

  2. Freedom From Nausea, Photophobia, and Phonophobia Postdose (DB1 and DB2)

    The percentage of subjects who were free from nausea, photophobia, and phonophobia at 15, 30, and 45 minutes and 1, 1.5, 2, 4, and 24 hours postdose compared between DFN-15 and placebo

    Time frame: 15 minutes to 24 hours postdose

  3. Time to Headache Pain Relief Postdose (DB1 and DB2)

    The time to headache pain relief was defined as the time in minutes from when a subject took study drug until the time pain relief was indicated by the subject in the eDiary within 2 hours postdose.

    Time frame: 2 hours postdose

  4. Time to Headache Pain Freedom Postdose (DB1 and DB2)

    The time to headache pain freedom was defined as the time in minutes from when a subject took study drug until the time pain freedom was indicated by the subject in the eDiary within 2 hours postdose.

    Time frame: 2 hours postdose

  5. Headache Pain Relief Postdose (DB1 and DB2)

    Headache pain relief was defined for DB1 as a reduction from moderate or severe pain before dosing to mild or none postdose, and for DB2 as moderate or severe pain before dosing reduced to mild or none postdose, or mild pain before dosing reduced to none postdose. Data are reported by percentage reporting headache pain relief over time postdose.

    Time frame: 15 minutes to 24 hours postdose

  6. Headache Pain Freedom Postdose (DB1 and DB2)

    The percentage of subjects who were pain-free at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2 period), 4, and 24 hours postdose compared between DFN-15 and placebo

    Time frame: 15 minutes to 24 hours postdose

  7. Absence of Screening MBS at Time Points Postdose (DB1 and DB2)

    The percentage of subjects with their Screening MBS (Most Bothersome Symptom) absent at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2 period), 4, and 24 hours postdose compared between DFN-15 and placebo.

    Time frame: 15 minutes to 24 hours postdose

  8. Change in Functional Disability Score Postdose (DB1 and DB2)

    Change in functional disability score at 2, 4, and 24 hours postdose compared between DFN-15 and placebo. The values of the functional disability scale were: 0=no disability, able to function normally; 1=performance of daily activities mildly impaired, can still do everything but with difficulty; 2=performance of daily activities moderately impaired, unable to do some things; 3=performance of daily activities severely impaired, cannot do all or most things, bed rest may be necessary. A decrease in values indicates improvement from baseline.

    Time frame: 2 to 24 hours postdose

  9. Headache Pain Freedom Among Subjects With Cutaneous Allodynia (DB1 and DB2)

    The percentage of subjects who were pain-free at 2 and 4 hours postdose compared between DFN-15 and placebo, among those reporting cutaneous allodynia predose

    Time frame: 2 and 4 hours postdose

  10. Headache Pain Freedom Among BMI Category (DB1 and DB2)

    The percentage of subjects who were pain-free at 2 and 4 hours postdose whose BMI was \< 30 kg/m2 vs. subjects whose BMI was ≥ 30 kg/m2, and whose BMI was \< 25 kg/m2 vs. subjects whose BMI was ≥ 25 kg/m2

    Time frame: 2 and 4 hours postdose

  11. Headache Pain Recurrence Postdose (DB1 and DB2)

    The percentage of subjects who had pain recurrence between 2 to 24 hours (i.e., pain-free at 2 hours postdose, with pain \[mild, moderate, or severe\] reported at 24 hours postdose) compared between DFN-15 and placebo

    Time frame: 2 to 24 hours postdose

  12. Sustained Headache Pain Relief Postdose (DB1 and DB2)

    The percentage of the population of subjects who reported headache pain relief between 2 and 24 hours postdose.

    Time frame: 2 to 24 hours postdose

  13. Sustained Headache Pain Freedom Postdose (DB1 and DB2)

    The percentage of subjects who had sustained pain freedom at 2 to 24 hours postdose compared between DFN-15 and placebo in each DB period. Sustained pain freedom at 2 to 24 hours postdose is defined as pain-free at 2 hours postdose, with no use of rescue medication, and no recurrence of headache pain within 2 to 24 hours postdose

    Time frame: 2 to 24 hours postdose

  14. Use of Rescue Medication Postdose (DB1 and DB2)

    The percentage of subjects who used rescue medication after 2 hours (2 to 24 hours) postdose compared between DFN-15 and placebo in each DB period

    Time frame: 2 to 24 hours postdose

  15. Subject-Rated Treatment Satisfaction Postdose (DB1 and DB2)

    Subject-rated treatment overall satisfaction was based on a 7-point scale at 2 and 4 hours postdose during each DB treatment period. The difference between the subject-rated study drug treatment satisfaction score at 2 and 4 hours postdose and the baseline PPMQ-R (Patient Perception of Migraine Questionnaire) response for the same question were summarized by treatment group (global satisfaction item at baseline asked about the subject's usual migraine treatment). The possible values of the subject treatment satisfaction scale were: 1=very satisfied, 2=satisfied, 3=somewhat satisfied, 4=neither satisfied nor dissatisfied, 5=somewhat dissatisfied, 6=dissatisfied, 7=very dissatisfied. A decrease in values indicates improvement from baseline.

    Time frame: 2 and 4 hours postdose

  16. Subject-Rated Treatment Satisfaction at 24 Hours Postdose - PPMQ-R (DB1 and DB2)

    Patient Perception of Migraine Questionnaire-Revised had 30 questions assessing subject's satisfaction with migraine medication, including 3 global items \& 4 subscales (i.e., efficacy, function, ease of use, tolerability). A 5-point scale (1-Not At All to 5-Extremely) was used for tolerability subscale questions; a 7-point scale (1-Very Satisfied to 7-Very Dissatisfied) was used for all other subscales and global items. Total score was average of efficacy/function/ease of use subscale scores. Each subscale \& total scores were transformed to range from 0-100, with higher scores indicating better satisfaction or tolerability. Total raw score/global items were not transformed. The total raw score could range from 17 (min) to 119 (max), with lower scores indicating better satisfaction. Change from baseline scores at 24-hour-postdose for each subscale score, global item score, total score, \& total raw score were summarized by treatment group below.

    Time frame: 24 hours postdose

07

Results

Posted Jan 10, 2023

Participant flow

Double-blind Period 1 (DB1)
Participant flow — Double-blind Period 1 (DB1)
MilestoneDFN-15Placebo
Started316315
Completed280264
Not completed3651
Double-blind Period 2 (DB2)
Participant flow — Double-blind Period 2 (DB2)
MilestoneDFN-15Placebo
Started272273
Completed251253
Not completed2120

Outcome measures

PrimaryPercentage of Subjects Who Are Pain-free at 2 Hours Postdose (First Treated Double-blind Treatment Period)

The primary efficacy end point (for first treated DB1 attack only) were the percentage of subjects who were pain-free 2 hours postdose compared between DFN-15 and placebo (defined as a reduction from predose moderate \[Grade 2\] or severe \[Grade 3\] pain to none \[Grade 0\]

Time frame:
2 hours postdose
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (First Treated Double-blind Treatment Period)
percentage of subjectsDFN-15 Placebo (LOCF)DFN-15 Active (LOCF)DFN-15 Placebo (OC)DFN-15 Active (OC)
Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (First Treated Double-blind Treatment Period)25.8 (20.7 to 31.5)32.9 (27.4 to 38.7)24.6 (19.5 to 30.4)32.4 (26.9 to 38.2)
Statistical analysis
  • DFN-15 Placebo (LOCF) vs DFN-15 Active (LOCF) · Fisher Exact · p = 0.075 · Odds ratio (or): 1.40 · 95% CI 0.97 to 2.03
  • DFN-15 Placebo (OC) vs DFN-15 Active (OC) · Fisher Exact · p = 0.055 · Odds ratio (or): 1.47 · 95% CI 1.00 to 2.14
PrimaryPercentage of Subjects Who Are Free From Their MBS at 2 Hours Postdose

Percentage of subjects who are free from their Most Bothersome Symptom (MBS) among nausea, photophobia, and phonophobia (first double-blind treatment period)

Time frame:
2 hours postdose
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Are Free From Their MBS at 2 Hours Postdose
percentage of subjectsDFN-15 Placebo (LOCF)DFN-15 Active (LOCF)DFN-15 Placebo (OC)DFN-15 Active (OC)
Percentage of Subjects Who Are Free From Their MBS at 2 Hours Postdose45.0 (38.5 to 51.7)58.9 (52.4 to 65.2)44.4 (37.8 to 51.2)58.5 (51.9 to 64.8)
Statistical analysis
  • DFN-15 Placebo (LOCF) vs DFN-15 Active (LOCF) · Regression, Logistic · p = 0.003 · Odds ratio (or): 1.75 · 95% CI 1.22 to 2.52
  • DFN-15 Placebo (OC) vs DFN-15 Active (OC) · Regression, Logistic · p = 0.003 · Odds ratio (or): 1.76 · 95% CI 1.22 to 2.55
SecondaryThe Number of Subjects With TEAEs After Study Drug Compared Between DFN-15 and Placebo

For DB1: TEAE that started or worsening of a pre-existing condition on or after the first dose of study drug (DFN-15 or placebo) in to taking DB2 study drug, whichever occurs first. For DB2: TEAE that started or worsened on or after the first dose of study drug in DB2 up to 5 days after the date of the last dose of study drug in DB2.

Time frame:
Per protocol, the maximum dosing timeframe for DB2 was 10 weeks; therefore, the maximum AE collection window was 11 weeks total.
Reported as:
Count of participants · Participants
The Number of Subjects With TEAEs After Study Drug Compared Between DFN-15 and Placebo
ParticipantsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
The Number of Subjects With TEAEs After Study Drug Compared Between DFN-15 and Placebo28312621
SecondaryFreedom From Nausea, Photophobia, and Phonophobia Postdose (DB1 and DB2)

The percentage of subjects who were free from nausea, photophobia, and phonophobia at 15, 30, and 45 minutes and 1, 1.5, 2, 4, and 24 hours postdose compared between DFN-15 and placebo

Time frame:
15 minutes to 24 hours postdose
Reported as:
Number · percentage of subjects
Freedom From Nausea, Photophobia, and Phonophobia Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1 NauseaDFN-15 DB1 NauseaPlacebo DB1 PhotophobiaDFN-15 DB1 PhotophobiaPlacebo DB1 PhonophobiaDFN-15 DB1 PhonophobiaPlacebo DB2 NauseaDFN-15 DB2 NauseaPlacebo DB2 PhotophobiaDFN-15 DB2 PhotophobiaPlacebo DB2 PhonophobiaDFN-15 DB2 Phonophobia
15 minutes postdose20.3 (13.7 to 28.3)14.3 (8.8 to 21.4)6.2 (3.3 to 10.3)9.0 (5.5 to 13.6)11.1 (6.9 to 16.6)15.5 (10.5 to 21.8)10.4 (5.1 to 18.3)16.2 (9.7 to 24.7)3.3 (1.2 to 7.1)10.4 (6.4 to 15.8)8.7 (4.7 to 14.4)13.2 (8.1 to 19.8)
30 minutes postdose35.3 (27.3 to 43.9)32.4 (25.0 to 40.6)14.7 (10.3 to 20.0)15.9 (11.4 to 21.2)16.8 (11.8 to 22.8)24.5 (18.5 to 31.3)27.5 (19.1 to 37.2)27.2 (19.3 to 36.3)15.0 (10.3 to 20.9)21.2 (15.7 to 27.6)19.5 (13.6 to 26.5)25.9 (19.3 to 33.5)
45 minutes postdose40.3 (32.1 to 48.9)44.4 (36.3 to 52.7)22.8 (17.5 to 28.8)25.2 (19.8 to 31.2)29.4 (23.1 to 36.3)33.9 (27.2 to 41.0)40.4 (31.2 to 50.9)44.0 (34.8 to 53.5)25.3 (19.3 to 32.0)30.2 (23.9 to 37.0)29.2 (22.3 to 36.9)36.9 (29.4 to 44.9)
1 hour postdose45.8 (37.4 to 54.3)55.9 (47.6 to 64.0)25.9 (20.4 to 32.0)32.0 (26.1 to 38.2)32.5 (26.0 to 39.5)39.5 (32.6 to 46.7)55.1 (45.2 to 65.8)56.9 (47.4 to 66.1)30.8 (24.5 to 37.7)37.2 (30.5 to 44.3)38.2 (30.7 to 46.1)48.1 (40.2 to 56.2)
1.5 hours postdose53.5 (45.0 to 61.9)58.8 (50.6 to 66.7)35.6 (29.5 to 42.1)46.3 (39.9 to 52.8)40.9 (34.0 to 48.1)52.0 (44.8 to 59.2)58.9 (49.0 to 68.3)62.9 (53.5 to 71.7)42.2 (35.3 to 49.4)48.2 (41.1 to 55.4)52.4 (44.5 to 60.2)55.6 (47.6 to 63.5)
2 hours postdose60.4 (51.9 to 68.5)66.7 (58.6 to 74.1)42.9 (36.5 to 49.4)58.0 (51.5 to 64.3)47.0 (40.0 to 54.2)59.2 (52.0 to 66.1)68.5 (58.9 to 77.1)72.9 (63.9 to 80.7)50.3 (43.1 to 57.4)53.7 (46.6 to 60.7)53.9 (46.0 to 61.6)61.3 (53.4 to 68.9)
4 hours postdose74.0 (66.1 to 80.9)83.0 (76.1 to 88.6)57.5 (51.0 to 63.8)70.5 (64.3 to 76.1)65.2 (58.2 to 71.7)68.5 (61.5 to 74.9)73.1 (63.8 to 81.2)84.0 (76.2 to 90.1)61.0 (53.9 to 67.8)73.7 (67.1 to 79.5)69.5 (61.9 to 76.3)75.8 (65.5 to 82.1)
24 hours postdose89.1 (82.9 to 93.6)89.6 (83.7 to 93.9)83.9 (78.6 to 88.3)86.5 (81.6 to 90.5)82.5 (76.6 to 87.4)88.9 (83.7 to 92.9)90.8 (83.8 to 95.5)93.3 (87.3 to 97.1)85.7 (80.1 to 90.2)90.4 (85.5 to 94.0)87.6 (81.7 to 92.2)89.2 (83.5 to 93.5)
SecondaryTime to Headache Pain Relief Postdose (DB1 and DB2)

The time to headache pain relief was defined as the time in minutes from when a subject took study drug until the time pain relief was indicated by the subject in the eDiary within 2 hours postdose.

Time frame:
2 hours postdose
Reported as:
Mean · time (hours)
Time to Headache Pain Relief Postdose (DB1 and DB2)
time (hours)Placebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Time to Headache Pain Relief Postdose (DB1 and DB2)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryTime to Headache Pain Freedom Postdose (DB1 and DB2)

The time to headache pain freedom was defined as the time in minutes from when a subject took study drug until the time pain freedom was indicated by the subject in the eDiary within 2 hours postdose.

Time frame:
2 hours postdose
Reported as:
Median · time (minutes)
Time to Headache Pain Freedom Postdose (DB1 and DB2)
time (minutes)Placebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Time to Headache Pain Freedom Postdose (DB1 and DB2)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryHeadache Pain Relief Postdose (DB1 and DB2)

Headache pain relief was defined for DB1 as a reduction from moderate or severe pain before dosing to mild or none postdose, and for DB2 as moderate or severe pain before dosing reduced to mild or none postdose, or mild pain before dosing reduced to none postdose. Data are reported by percentage reporting headache pain relief over time postdose.

Time frame:
15 minutes to 24 hours postdose
Reported as:
Number · percentage of subjects
Headache Pain Relief Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
15 minutes postdose12.6 (8.6 to 17.4)12.6 (8.7 to 17.3)7.9 (4.7 to 12.3)15.0 (10.5 to 20.4)
30 minutes postdose22.4 (17.5 to 28.1)25.3 (20.2 to 30.9)23.0 (17.8 to 29.0)28.0 (22.3 to 34.3)
45 minutes postdose35.0 (29.2 to 41.2)40.0 (34.2 to 46.1)35.3 (29.2 to 41.9)40.0 (33.7 to 46.6)
1 hour postdose39.8 (33.9 to 46.1)49.6 (43.6 to 55.7)41.9 (35.6 to 48.5)52.8 (46.2 to 59.3)
1.5 hours postdose49.6 (43.4 to 55.8)58.8 (52.8 to 64.6)51.9 (45.3 to 58.4)62.7 (56.2 to 68.9)
2 hours postdose56.9 (50.8 to 62.9)68.6 (62.8 to 74.0)58.6 (52.0 to 64.9)69.6 (63.3 to 75.3)
4 hours postdose73.8 (68.1 to 78.9)82.9 (78.0 to 87.1)74.6 (68.6 to 80.0)84.7 (79.5 to 89.0)
24 hours postdose92.7 (89.0 to 95.5)94.3 (90.9 to 96.7)88.2 (83.4 to 91.9)95.1 (91.6 to 97.4)
SecondaryHeadache Pain Freedom Postdose (DB1 and DB2)

The percentage of subjects who were pain-free at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2 period), 4, and 24 hours postdose compared between DFN-15 and placebo

Time frame:
15 minutes to 24 hours postdose
Reported as:
Number · percentage of subjects
Headache Pain Freedom Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
15 minutes postdose2.9 (1.2 to 5.9)1.2 (0.3 to 3.5)0.5 (0.0 to 2.6)2.8 (1.0 to 6.0)
30 minutes postdose5.5 (3.0 to 9.1)3.7 (1.8 to 6.7)1.7 (0.5 to 4.4)8.6 (5.3 to 13.0)
45 minutes postdose9.7 (6.4 to 14.0)9.5 (6.3 to 13.5)7.3 (4.3 to 11.5)11.9 (8.1 to 16.8)
1 hour postdose12.6 (8.9 to 17.3)18.0 (13.7 to 23.0)11.9 (8.0 to 16.7)18.7 (13.9 to 24.3)
1.5 hours postdose19.8 (15.2 to 25.2)24.7 (19.8 to 30.2)20.7 (15.7 to 26.4)27.1 (21.6 to 33.3)
2 hours postdose——24.3 (19.0 to 30.2)36.7 (30.6 to 43.1)
4 hours postdose40.2 (34.3 to 46.3)49.1 (43.1 to 55.1)46.7 (40.2 to 53.2)59.1 (52.6 to 65.3)
24 hours postdose71.9 (66.2 to 77.1)79.4 (74.2 to 84.0)74.7 (68.8 to 80.0)85.3 (80.2 to 89.5)
SecondaryAbsence of Screening MBS at Time Points Postdose (DB1 and DB2)

The percentage of subjects with their Screening MBS (Most Bothersome Symptom) absent at 15, 30, and 45 minutes and 1, 1.5, 2 (DB2 period), 4, and 24 hours postdose compared between DFN-15 and placebo.

Time frame:
15 minutes to 24 hours postdose
Reported as:
Number · percentage of subjects
Absence of Screening MBS at Time Points Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
15 minutes postdose8.3 (4.9 to 12.9)10.4 (6.6 to 15.3)5.8 (2.8 to 10.5)9.6 (5.7 to 14.9)
30 minutes postdose17.0 (12.2 to 22.6)18.2 (13.4 to 23.8)16.4 (11.3 to 22.6)21.5 (15.9 to 28.0)
45 minutes postdose24.0 (18.5 to 30.2)29.1 (23.4 to 35.3)28.1 (21.8 to 35.2)31.1 (24.6 to 38.1)
1 hour postdose27.6 (21.8 to 33.9)36.0 (29.9 to 42.4)32.3 (25.7 to 39.4)42.0 (34.9 to 49.3)
1.5 hours postdose38.1 (31.7 to 44.7)48.8 (42.3 to 55.3)44.7 (37.5 to 52.1)51.8 (44.5 to 59.0)
2 hours postdose45.0 (38.5 to 51.7)58.9 (52.4 to 65.2)51.3 (44.0 to 58.6)56.9 (49.7 to 64.0)
4 hours postdose61.4 (54.8 to 67.7)70.1 (36.9 to 75.8)61.5 (54.2 to 68.4)75.6 (69.0 to 81.5)
24 hours postdose83.8 (78.4 to 88.2)86.4 (81.4 to 90.4)86.7 (81.1 to 91.1)91.0 (86.1 to 94.6)
SecondaryChange in Functional Disability Score Postdose (DB1 and DB2)

Change in functional disability score at 2, 4, and 24 hours postdose compared between DFN-15 and placebo. The values of the functional disability scale were: 0=no disability, able to function normally; 1=performance of daily activities mildly impaired, can still do everything but with difficulty; 2=performance of daily activities moderately impaired, unable to do some things; 3=performance of daily activities severely impaired, cannot do all or most things, bed rest may be necessary. A decrease in values indicates improvement from baseline.

Time frame:
2 to 24 hours postdose
Reported as:
Mean · units on a scale
Change in Functional Disability Score Postdose (DB1 and DB2)
units on a scalePlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
2 hours postdose-0.7 ± 0.95-0.9 ± 0.89-0.6 ± 0.94-0.9 ± 0.91
4 hours postdose-1.0 ± 1.06-1.2 ± 0.89-0.9 ± 0.97-1.2 ± 0.90
24 hours postdose-1.7 ± 0.92-1.7 ± 0.78-1.5 ± 0.84-1.7 ± 0.82
SecondaryHeadache Pain Freedom Among Subjects With Cutaneous Allodynia (DB1 and DB2)

The percentage of subjects who were pain-free at 2 and 4 hours postdose compared between DFN-15 and placebo, among those reporting cutaneous allodynia predose

Time frame:
2 and 4 hours postdose
Reported as:
Number · percentage of subjects
Headache Pain Freedom Among Subjects With Cutaneous Allodynia (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
2 hours postdose26.2 (16.0 to 38.5)26.2 (15.8 to 39.1)25.5 (14.3 to 39.6)39.5 (25.0 to 55.6)
4 hours postdose37.9 (26.2 to 50.7)39.3 (27.1 to 52.7)43.1 (29.3 to 57.8)54.5 (38.8 to 69.6)
SecondaryHeadache Pain Freedom Among BMI Category (DB1 and DB2)

The percentage of subjects who were pain-free at 2 and 4 hours postdose whose BMI was \< 30 kg/m2 vs. subjects whose BMI was ≥ 30 kg/m2, and whose BMI was \< 25 kg/m2 vs. subjects whose BMI was ≥ 25 kg/m2

Time frame:
2 and 4 hours postdose
Reported as:
Number · percentage of subjects
Headache Pain Freedom Among BMI Category (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
2 hours postdose (BMI<30)22.9 (16.3 to 30.7)25.6 (19.0 to 33.2)22.1 (15.1 to 30.5)34.3 (26.5 to 42.8)
4 hours postdose (BMI<30)38.1 (30.2 to 46.5)43.6 (35.7 to 51.8)44.3 (35.3 to 53.5)55.0 (46.4 to 63.4)
2 hours postdose (BMI>=30)29.3 (21.4 to 38.1)41.9 (33.1 to 51.1)26.5 (18.8 to 35.5)40.0 (30.3 to 50.3)
4 hours postdose (BMI>=30)42.7 (33.9 to 51.9)56.0 (46.8 to 64.9)49.2 (39.8 to 58.5)64.7 (54.6 to 73.9)
SecondaryHeadache Pain Recurrence Postdose (DB1 and DB2)

The percentage of subjects who had pain recurrence between 2 to 24 hours (i.e., pain-free at 2 hours postdose, with pain \[mild, moderate, or severe\] reported at 24 hours postdose) compared between DFN-15 and placebo

Time frame:
2 to 24 hours postdose
Reported as:
Number · percentage of subjects
Headache Pain Recurrence Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Headache Pain Recurrence Postdose (DB1 and DB2)10.1 (4.2 to 19.8)7.6 (3.1 to 15.1)6.9 (1.9 to 16.7)4.5 (1.3 to 11.1)
SecondarySustained Headache Pain Relief Postdose (DB1 and DB2)

The percentage of the population of subjects who reported headache pain relief between 2 and 24 hours postdose.

Time frame:
2 to 24 hours postdose
Reported as:
Number · percentage of subjects
Sustained Headache Pain Relief Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Sustained Headache Pain Relief Postdose (DB1 and DB2)39.8 (33.0 to 46.9)55.1 (48.4 to 61.7)44.3 (37.0 to 51.8)56.6 (49.1 to 63.9)
SecondarySustained Headache Pain Freedom Postdose (DB1 and DB2)

The percentage of subjects who had sustained pain freedom at 2 to 24 hours postdose compared between DFN-15 and placebo in each DB period. Sustained pain freedom at 2 to 24 hours postdose is defined as pain-free at 2 hours postdose, with no use of rescue medication, and no recurrence of headache pain within 2 to 24 hours postdose

Time frame:
2 to 24 hours postdose
Reported as:
Number · percentage of subjects
Sustained Headache Pain Freedom Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Sustained Headache Pain Freedom Postdose (DB1 and DB2)18.9 (13.7 to 25.0)27.6 (21.8 to 33.9)20.0 (14.5 to 26.5)29.1 (22.6 to 36.3)
SecondaryUse of Rescue Medication Postdose (DB1 and DB2)

The percentage of subjects who used rescue medication after 2 hours (2 to 24 hours) postdose compared between DFN-15 and placebo in each DB period

Time frame:
2 to 24 hours postdose
Reported as:
Number · percentage of subjects
Use of Rescue Medication Postdose (DB1 and DB2)
percentage of subjectsPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Use of Rescue Medication Postdose (DB1 and DB2)28.5 (23.2 to 34.2)18.8 (14.4 to 23.9)22.9 (17.8 to 28.6)18.4 (13.7 to 23.8)
SecondarySubject-Rated Treatment Satisfaction Postdose (DB1 and DB2)

Subject-rated treatment overall satisfaction was based on a 7-point scale at 2 and 4 hours postdose during each DB treatment period. The difference between the subject-rated study drug treatment satisfaction score at 2 and 4 hours postdose and the baseline PPMQ-R (Patient Perception of Migraine Questionnaire) response for the same question were summarized by treatment group (global satisfaction item at baseline asked about the subject's usual migraine treatment). The possible values of the subject treatment satisfaction scale were: 1=very satisfied, 2=satisfied, 3=somewhat satisfied, 4=neither satisfied nor dissatisfied, 5=somewhat dissatisfied, 6=dissatisfied, 7=very dissatisfied. A decrease in values indicates improvement from baseline.

Time frame:
2 and 4 hours postdose
Reported as:
Mean · units on a scale
Subject-Rated Treatment Satisfaction Postdose (DB1 and DB2)
units on a scalePlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Difference at 2 hours0.7 ± 2.49-0.1 ± 2.350.3 ± 2.45-0.1 ± 2.26
Difference at 4 hours0.7 ± 2.50-0.1 ± 2.360.4 ± 2.46-0.1 ± 2.29
SecondarySubject-Rated Treatment Satisfaction at 24 Hours Postdose - PPMQ-R (DB1 and DB2)

Patient Perception of Migraine Questionnaire-Revised had 30 questions assessing subject's satisfaction with migraine medication, including 3 global items \& 4 subscales (i.e., efficacy, function, ease of use, tolerability). A 5-point scale (1-Not At All to 5-Extremely) was used for tolerability subscale questions; a 7-point scale (1-Very Satisfied to 7-Very Dissatisfied) was used for all other subscales and global items. Total score was average of efficacy/function/ease of use subscale scores. Each subscale \& total scores were transformed to range from 0-100, with higher scores indicating better satisfaction or tolerability. Total raw score/global items were not transformed. The total raw score could range from 17 (min) to 119 (max), with lower scores indicating better satisfaction. Change from baseline scores at 24-hour-postdose for each subscale score, global item score, total score, \& total raw score were summarized by treatment group below.

Time frame:
24 hours postdose
Reported as:
Mean · units on a scale
Subject-Rated Treatment Satisfaction at 24 Hours Postdose - PPMQ-R (DB1 and DB2)
units on a scalePlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2
Total Score-4.866 ± 32.62585.112 ± 30.6380.491 ± 32.54876.691 ± 28.1563
Total Raw Score2.463 ± 12.7476-1.498 ± 12.02090.426 ± 12.8385-2.312 ± 11.0429
Efficacy-9.591 ± 41.08223.016 ± 38.9173-3.261 ± 41.66316.044 ± 36.1736
Function-3.812 ± 42.09958.554 ± 39.42482.559 ± 42.377310.708 ± 35.2324
Ease of Use-1.197 ± 29.13093.766 ± 26.08052.174 ± 27.79243.360 ± 23.7033
Tolerability6.09 ± 14.8506.98 ± 15.2675.87 ± 14.1157.62 ± 17.579
Medication effectiveness (Global Item)0.9 ± 2.800.1 ± 2.640.6 ± 2.65-0.1 ± 2.43
Side Effects (Global Item)-0.5 ± 2.00-0.4 ± 1.88-0.2 ± 1.98-0.5 ± 2.00
Overall Satisfaction (Global Item)0.8 ± 2.740.1 ± 2.600.5 ± 2.65-0.1 ± 2.41

Adverse events

Collected over Per protocol, the maximum dosing timeframe for DB2 was 10 weeks; therefore, the maximum AE collection window was 11 weeks total.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo DB10/283 (0%)2/283 (0.7%)5/283 (1.8%)
DFN-15 DB10/289 (0%)1/289 (0.3%)4/289 (1.4%)
Placebo DB20/254 (0%)0/254 (0%)3/254 (1.2%)
DFN-15 DB20/251 (0%)1/251 (0.4%)4/251 (1.6%)
Overall0/572 (0%)4/572 (0.7%)13/572 (2.3%)
Most frequent serious events
Most frequent serious events
EventPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2Overall
CystitisRenal and urinary disorders0/2830/2890/2541/2511/572
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/2830/2890/2540/2511/572
Non-cardiac chest painNervous system disorders1/2830/2890/2540/2511/572
Pulmonary embolismCardiac disorders0/2831/2890/2540/2511/572
Most frequent other events
Most frequent other events
EventPlacebo DB1DFN-15 DB1Placebo DB2DFN-15 DB2Overall
NauseaGastrointestinal disorders5/2834/2893/2544/25113/572

Baseline characteristics

Safety Set 1 (for DB1)

Age, Continuous
Age, Continuous(Years)DB1 PlaceboDB1 DFN-15Total
Mean40.4 ± 12.9941.4 ± 13.9441.0 ± 13.44
Sex: Female, Male
Sex: Female, Male(Participants)DB1 PlaceboDB1 DFN-15Total
Female245237482
Male385290
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DB1 PlaceboDB1 DFN-15Total
Hispanic or Latino414081
Not Hispanic or Latino241248489
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DB1 PlaceboDB1 DFN-15Total
American Indian or Alaska Native000
Asian314
Native Hawaiian or Other Pacific Islander000
Black or African American6364127
White209214423
More than one race000
Unknown or Not Reported81018
08

Study locations

43 sites
  • Site 609
    Birmingham, Alabama 35205, United States
  • Site 640
    Mobile, Alabama 36608, United States
  • Site 622
    Tucson, Arizona 85745, United States
  • Site 616
    Hot Springs, Arkansas 71901, United States
  • Site 637
    Huntington Beach, California 92647, United States
  • Site 615
    Oakland, California 94607, United States
  • Site 646
    San Diego, California 92108, United States
  • Site 619
    San Francisco, California 94102, United States
  • Site 624
    San Marcos, California 92078, United States
  • Site 631
    Littleton, Colorado 80127, United States
  • Site 603
    Miami, Florida 33176, United States
  • Site 641
    Orange City, Florida 32763, United States
  • Site 629
    Orlando, Florida 32801, United States
  • Site 601
    West Palm Beach, Florida 33409, United States
  • Site 625
    Decatur, Georgia 30034, United States
  • Site 630
    Sandy Springs, Georgia 30328, United States
  • Site 642
    Meridian, Idaho 83642, United States
  • Site 604
    Blue Island, Illinois 60406, United States
  • Site 602
    Louisville, Kentucky 40213, United States
  • Site 644
    New Orleans, Louisiana 70115, United States
  • Site 610
    New Orleans, Louisiana 70124, United States
  • Site 634
    Ann Arbor, Michigan 48104, United States
  • Site 623
    Edina, Minnesota 55435, United States
  • Site 638
    Saint Peters, Missouri 63303, United States
  • Site 606
    Missoula, Montana 59808, United States
  • Site 613
    Omaha, Nebraska 68134, United States
  • Site 647
    Lebanon, New Hampshire 03756, United States
  • Site 618
    Nashua, New Hampshire 03060, United States
  • Site 636
    Albuquerque, New Mexico 87102, United States
  • Site 645
    Brooklyn, New York 11229, United States
  • Site 608
    Rochester, New York 14609, United States
  • Site 620
    High Point, North Carolina 27262, United States
  • Site 643
    Mooresville, North Carolina 28117, United States
  • Site 626
    Fargo, North Dakota 58103, United States
  • Site 628
    Cleveland, Ohio 44122, United States
  • Site 614
    Warwick, Rhode Island 02886, United States
  • Site 639
    Mount Pleasant, South Carolina 29464, United States
  • Site 612
    Dakota Dunes, South Dakota 57049, United States
  • Site 627
    Austin, Texas 78745, United States
  • Site 611
    Dallas, Texas 75231, United States
  • Site 632
    San Antonio, Texas 78240, United States
  • Site 621
    Taylorsville, Utah 84123, United States
  • Site 635
    Richmond, Virginia 23294, United States
09

References and documents

Publications

  • Lipton RB, Munjal S, Tepper SJ, Iaconangelo C, Serrano D. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura. J Pain Res. 2021 Aug 19;14:2529-2542. doi: 10.2147/JPR.S322292. eCollection 2021. PubMed 34447267 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2016, a primary completion of Nov 2017 and a completion of May 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2023, 5 years 2 months after primary completion. A results delay was requested in Dec 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2016
First posted
Jan 4, 2017
Start
Dec 2016
Primary completionActual
Nov 2017
CompletionActual
May 2019
Results delay requested
Dec 24, 2018
Results first posted
Jan 10, 2023
Last update
Jan 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03009019
Lead sponsor
BioDelivery Sciences International
Responsible party
Sponsor
First posted
Jan 4, 2017
Start date
Dec 2016
Primary completion
Nov 2017
Completion
May 2019
Results posted
Jan 10, 2023
Last update
Jan 10, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion